Monday, May 23, 2016

The Future of Hep C Treatment

The Future of Hep C Treatment
Posted By: DDW Communications
on: May 23, 2016
In: AASLD, By Society, Explore Sessions, Watch Videos

DDW TV covered this exciting and informative State-of-the-Art Lecture which presented the very latest information on hepatitis C. We talked to the session’s speaker, Norah Terrault, MD, MPH, about a range of new therapies coming out that will help difficult to treat populations. Dr. Terrault also talks about the future – and what the discussions around hepatitis C are likely to be in 2017.

DDW 2016 abstracts are available via the Online Planner
1 - Click on Abstracts
2 - Under Abstract Category​ click on hepatitis C

Of Interest
May 24
Digestive Disease Week 2016
ASTRAL studies: New combination yields encouraging patient-reported outcomes
SAN DIEGO —   Treatment with velpatasvir/sofosbuvir was associated with improvements in a number of patient self-reported quality of life measures, according to findings presented at Digestive Disease Week 2016.

May 13
THE FIVE The International Liver Congress
Alan Franciscus, Editor-in-Chief

Gilead Sciences (GILD) Presents at 2016 UBS Global Healthcare Brokers Conference - Transcript
May 23
We have a few other programs in clinical development, the first one is a combination of sofosbuvir and velpatasvir, this is a once-daily Pan-Genotypic single-tablet regimen, the NDA was filed late last year and we've a PDUFA date coming up next month, June 28th. And in the United in the -- this was by the way joined the priority of review and in the Europe we have the similar timelines....
*Free registration required

Sofosbuvir/Velpatasvir (SOF/VEL) and SOF/VEL Plus GS-9857
Gilead's Press Release
Gilead's Sofosbuvir/Velpatasvir and SOF/VEL Plus GS-9857 at The International Liver CongressTM
– Studies Highlight Progress with Approved Therapies and Investigational Pangenotypic Regimens, Including Sofosbuvir/Velpatasvir (SOF/VEL) and SOF/VEL Plus GS-9857 –

April 14
Sofosbuvir/Velpatasvir (SOF/VEL) and SOF/VEL Plus GS-9857 
The International Liver Congress 2016 Press Release
Sofosbuvir/velpatasvir and experimental compound GS-9857 shows promise in Hepatitis C infected patients whose previous treatment has failed
High sustained virologic response achieved with sofosbuvir/velpatasvir and GS-9857, even in patients unsuccessfuly treated with direct-acting antivirals

Nam aidsmap
Sofosbuvir/Velpatasvir (SOF/VEL) and SOF/VEL Plus GS-9857
Reported by Liz Highleyman
Sofosbuvir/velpatasvir + GS-9857 works well for treatment-experienced hepatitis C patients
A triple combination of Gilead Sciences' sofosbuvir, velpatasvir and GS-9857 demonstrated a high sustained response rate for treatment-experienced people with all hepatitis C virus (HCV) genotypes who previously were not cured with prior direct-acting antivirals (DAAs), according to two presentations yesterday at the 2016 International Liver Congress in Barcelona.Interferon-free DAA therapy has revolutionised treatment for chronic hepatitis C, but there is still room to optimise therapy for difficult-to-treat patients. Ideally such regimens will be pangenotypic, meaning they could be routinely prescribed without the need for HCV genotype testing.
Eric Lawitz of the Texas Liver Institute presented findings from studies of a three-drug regimen consisting of the HCV NS5B polymerase inhibitor sofosbuvir (Sovaldi), the pangenotypic second-generation NS5A inhibitor velpatasvir (formerly GS-5816), and the investigational pangenotypic HCV NS3/4A protease inhibitor GS-9857. Combining drugs that attack multiple steps of the HCV lifecycle improves efficacy and may enable shorter treatment.

Sofosbuvir/Velpatasvir (SOF/VEL) and SOF/VEL Plus GS-9857 -

No comments:

Post a Comment